Short Interest in IceCure Medical Ltd (NASDAQ:ICCM) Decreases By 52.3%

IceCure Medical Ltd (NASDAQ:ICCM - Get Free Report) was the recipient of a significant drop in short interest during the month of March. As of March 15th, there was short interest totalling 285,500 shares, a drop of 52.3% from the February 28th total of 598,100 shares. Approximately 1.0% of the shares of the stock are sold short. Based on an average daily volume of 378,700 shares, the days-to-cover ratio is currently 0.8 days.

IceCure Medical Price Performance

NASDAQ ICCM traded up $0.06 during mid-day trading on Monday, hitting $1.17. The stock had a trading volume of 118,503 shares, compared to its average volume of 520,395. IceCure Medical has a 52-week low of $0.48 and a 52-week high of $1.66. The company has a quick ratio of 2.27, a current ratio of 2.67 and a debt-to-equity ratio of 0.02. The company has a 50 day simple moving average of $1.32 and a 200 day simple moving average of $0.99. The company has a market cap of $64.94 million, a price-to-earnings ratio of -4.03 and a beta of 0.37.

IceCure Medical (NASDAQ:ICCM - Get Free Report) last announced its quarterly earnings data on Thursday, March 27th. The company reported ($0.08) EPS for the quarter, missing analysts' consensus estimates of ($0.07) by ($0.01). The business had revenue of $1.07 million during the quarter, compared to analysts' expectations of $1.07 million. IceCure Medical had a negative net margin of 376.85% and a negative return on equity of 124.44%. Equities analysts forecast that IceCure Medical will post -0.28 EPS for the current fiscal year.

Remove Ads

Analysts Set New Price Targets

Separately, HC Wainwright reaffirmed a "buy" rating and issued a $2.50 price objective on shares of IceCure Medical in a research note on Friday.

Institutional Inflows and Outflows

A hedge fund recently raised its stake in IceCure Medical stock. XTX Topco Ltd boosted its holdings in IceCure Medical Ltd (NASDAQ:ICCM - Free Report) by 123.7% in the fourth quarter, according to the company in its most recent Form 13F filing with the Securities and Exchange Commission (SEC). The firm owned 58,866 shares of the company's stock after purchasing an additional 32,555 shares during the quarter. XTX Topco Ltd owned approximately 0.11% of IceCure Medical worth $65,000 at the end of the most recent quarter. 0.62% of the stock is owned by institutional investors.

IceCure Medical Company Profile

IceCure Medical Ltd, a commercial stage medical device company, engages in the research, development, and marketing of cryoablation systems, disposables, and technologies for treating tumors. The company offers ProSense system, a single probe system for the treatment of tumors, as well as associated disposables; and IceSense3 system for ablation indications to urology, oncology, dermatology, gynecology, general surgery, thoracic surgery, and proctology.